Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: AbbVie Inc.

Market Cap 392B 337B 311B 291B 547B 37,000B 553B 3,671B 1,434B 18,119B 1,469B 1,438B 62,699B P/E Ratio 2026 *
27.1x
P/E Ratio 2027 * 20.1x
Enterprise Value 445B 384B 353B 331B 623B 42,091B 629B 4,177B 1,631B 20,612B 1,671B 1,636B 71,325B EV / Sales 2026 *
6.62x
EV / Sales 2027 * 5.99x
Free-Float
95.71%
Yield 2026 *
3.1%
Yield 2027 * 3.26%
1 day+0.08%
1 week-0.66%
Current month+1.78%
1 month+5.32%
3 months+0.87%
6 months-2.58%
Current year-3.02%
1 week 220
Extreme 220
228.4
1 month 207.68
Extreme 207.68
230.47
Current year 190.75
Extreme 190.75
237.11
1 year 181.73
Extreme 181.73
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 105.56
Extreme 105.56
244.81
10 years 55.06
Extreme 55.0623
244.81
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 68 2012-12-31
Date Insider Type Main position Quantity % Market Cap.
05-07Free

Director

1,118 0.0001%
05-07Free

Director

1,118 0.0001%
05-07Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-2.70%-0.66%+15.97%+63.07% 392B
-0.32%-1.72%+37.83%+148.79% 1,007B
-2.16%+1.51%+50.01%+43.93% 567B
-0.31%+1.05%+20.91%+18.37% 328B
-0.52%+1.12%+24.21%+31.89% 277B
+0.80%-2.32%+23.09%+12.96% 275B
-0.49%+5.25%-43.05%-48.60% 196B
-1.31%+1.39%+18.74%+53.45% 189B
-1.03%-2.97%+13.02%+57.34% 154B
-0.80%+1.48%+5.95%-34.59% 148B
Average +0.13%+0.44%+16.67%+34.66% 353.42B
Weighted average by Cap. +0.22%+0.03%+25.64%+62.87%

Financials

2026 *2027 *
Net sales 67.23B 57.94B 53.33B 50.03B 93.97B 6,353B 94.91B 630B 246B 3,111B 252B 247B 10,766B 72.71B 62.66B 57.67B 54.1B 102B 6,871B 103B 682B 266B 3,365B 273B 267B 11,644B
Net income 14.85B 12.8B 11.78B 11.05B 20.76B 1,404B 20.97B 139B 54.41B 687B 55.75B 54.56B 2,379B 19.31B 16.64B 15.32B 14.37B 26.99B 1,825B 27.26B 181B 70.73B 894B 72.46B 70.93B 3,092B
Net Debt 53.86B 46.43B 42.73B 40.08B 75.29B 5,091B 76.04B 505B 197B 2,493B 202B 198B 8,626B 44.07B 37.98B 34.96B 32.79B 61.6B 4,165B 62.22B 413B 161B 2,040B 165B 162B 7,057B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-06-15 221.59 $ -2.70% 5,261,900
26-06-12 227.73 $ +1.32% 4,086,503
26-06-11 224.77 $ -0.08% 4,569,353
26-06-10 224.95 $ -0.21% 4,147,303
26-06-09 225.42 $ +1.05% 4,257,921
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
221.59USD
Average target price
253.55USD
Spread / Average Target
+14.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!